Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Alvotech. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alvotech (“Alvotech” or “the Company”) (NASDAQ: ALVO). Investors who purchased Alvotech securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Alvotech has violated federal securities laws.
Investigation Details
On November 2, 2025, Alvotech issued a press release “announc[ing]… that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab).” According to the press release, “[t]he CRL noted that certain deficiencies, which were conveyed following the FDA’s pre-license inspection of Alvotech’s Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved.” Following this news, Alvotech stock dropped $2.62 per share, or 34.25%, to close at $5.03 on November 3, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Alvotech securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
ALVO — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”